Obesity, Morbid
Conditions
Keywords
Obesity, Bariatric Surgery, Anti Obesity Medications, Weight Regulation, Pluripotent Stem Cells
Brief summary
This study aims to characterize the neurological basis of obesity and response to surgical and medical treatment by inducing adult pluripotent stem cells into neuronal cells from subjects that have demonstrated extreme response to bariatric surgery or pharmacological treatment for obesity.
Detailed description
The investigators will consent subjects who have achieved extreme response to either bariatric surgery or pharmacologic treatment for obesity and harvest fibroblasts from skin biopsies, which will be reprogrammed to induced pluripotent stem cells (iPSC). These iPSC's will then be differentiated into neural progenitor cells, neurons, astrocytes, and microglia to identify genetic and epigenetic pathways altered in disease-specific neural progenitor cells of the brain.
Interventions
PROCEDUREBariatric Surgery
Sleeve gastrectomy or Roux-en-Y Gastric Bypass
DRUGAnti Obesity Drugs
Response to FDA approved anti obesity medications
Sponsors
University of California, San Diego
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* History of obesity * Treatment with bariatric surgery * Treatment with anti obesity medications * Greater than 70% excess weight loss at least 6 months after surgery * Greater than 15% weight loss on anti obesity medications
Exclusion criteria
* Active cancer, not including non-melanoma skin cancer * Active eating disorder * Use of anti obesity medications in subjects with a history of bariatric surgery * Active complication of the upper GI tract in patients with a history of bariatric surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DNA sequencing | 4 months | Perform DNA sequencing from skin biopsy progenitor cells |
| Generate human cell based models of obesity | 4 months | Fibroblasts will be expanded in culture and then reprogrammed to hiPSCs. |
| Differentiation to human CNS cells | 4 months | Disease specific hiPSCs cells will be differentiated into neural progenitor cells, neurons, astrocytes, and microglia |
| Identification of genetic and epigenetic pathways | 4 months | Identify genetic and epigenetic pathways altered in disease-specific neural progenitor cells, neurons, and non-neuronal cells of the brain |
Countries
United States
Outcome results
None listed